Phelix Receives NIH Grant to Continue Research on Calpain Inhibitors for Pulmonary Fibrosis

Phelix Receives NIH Grant to Continue Research on Calpain Inhibitors for Pulmonary Fibrosis

Phelix Therapeutics has received a $201,665 National Institutes of Health (NIH) grant to continue studying  Calpain-based treatments for tissue-scarring diseases like idiopathic pulmonary fibrosis and the liver condition nonalcoholic steatohepatitis. Doctors need better treatments for scarring — or fibrosis — diseases, Phelix said. Current therapies address some of the inflammation that occurs in these…

Essential Oil Use with Pulmonary Fibrosis

With increasing interest in natural remedies for the management of disease symptoms, discussion about the uses of essential oils flourishes. Advocates for oil companies, such as dōTERRA or Young Living, will tell you that there are “unlimited” benefits and uses for these oils to help you live…

Gene Therapy Targeting Cause of Cellular Aging Treats Pulmonary Fibrosis in Mouse Study

Looking at pulmonary fibrosis (PF) as an age-related disease and working with a gene therapy that lengthens the life of lung cells, researchers report that they were able to lessen — and even stop — lung fibrosis in mice. “This is the first time that pulmonary fibrosis has been treated as an age-related disease, looking for rejuvenating the affected tissues,” Maria A. Blasco, study's lead author and group leader at the Spanish National Cancer Research Centre (CNIO), in Madrid, said in a press release. The study “Therapeutic effects of telomerase in mice with pulmonary fibrosis induced by damage to the lungs and short telomeres” was published in the journal eLife.

Why I’m Excited About the New PF Forum

Thinking back to my days of high school many years ago, I never imagined I would become involved with an online publication. I hated writing articles, papers, and essays, and I had little interest in research, chronic illness, or how words could be used to connect people so…

Phase 3 Trial Planned for PBI-4050, Potential Treatment for Mild-to-Moderate IPF Patients

A pivotal Phase 3 trial evaluating PBI-4050, a potential treatment of idiopathic pulmonary fibrosis, will be open to all patients with mild-to-moderate IPF regardless of whether they are also taking Ofev (nintedanib) or not, the therapy’s developer, Prometic Life Sciences, announced. The trial, in other words, will evaluate the efficacy and safety of…

Raising Awareness of Pulmonary Fibrosis

Did you know that pulmonary fibrosis takes as many lives as breast cancer or prostate cancer? However, unlike breast and prostate cancer, there is no remission and treatment can only ease the symptoms. Around 40,000 people die each year from pulmonary fibrosis in the U.S. yet very few people…

Gentiopicroside Effectively Fights Lung Fibrosis, Chinese Mouse Study Finds

A natural compound called gentiopicroside effectively lowers inflammation and tissue scarring in a mouse model of pulmonary fibrosis (PF), say researchers at China’s Kunming Medical University. Since the plant-derived compound targets both fibrotic and inflammatory processes, researchers suggested it may be an ideal drug candidate for lung fibrosis — particularly…